78 articles
Lotte Holdings, through its Healthcare & Biopharmaceutical Corporate Venture Capital (HB-CVC), has invested in Rakuten Medical, Inc., marking its eighth HB-CVC investment.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
Vetanic, which promotes animal regenerative medicine using iPS cells, has formed a capital and business alliance with Sysmex and Kohjin Bio to accelerate its initiatives.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.
H.U. Group has received manufacturing and marketing approval for its cancer genomic profiling system, 'Fujinokuni HOPE OncoPanel'.